Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy - PubMed (original) (raw)
. 2000 Aug 15;60(16):4556-60.
Affiliations
- PMID: 10969807
Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2 blockade, hormone ablation, and chemotherapy
N Hansen-Algenstaedt et al. Cancer Res. 2000.
Erratum in
- Cancer Res 2001 Aug 15;61(16):6304
Abstract
Tumor oxygenation is critical for tumor survival as well as for response to therapy, e.g., radiation therapy. Hormone ablation therapy in certain hormone-dependent tumors and antiangiogenic therapy lead to vessel regression and have also shown beneficial effects when combined with radiation therapy. These findings are counterintuitive because vessel regression should reduce oxygen tension (pO2) in tumors, decreasing the effectiveness of radiotherapy. Here we report on the dynamics of pO2 and oxygen consumption in a hormone-dependent tumor following hormone ablation and during treatment with an anti-VEGFR-2 monoclonal antibody (mAb) or a combination of doxorubicin and cyclophosphamide; the latter combination is not known to cause vessel regression at doses used clinically. Androgen-dependent male mouse mammary carcinoma (Shionogi) was implanted into transparent dorsal skin-fold chambers in male severe combined immunodeficient mice. Thirteen days after the tumors were implanted, mice were treated with antiangiogenic therapy (anti-VEGFR-2 mAb, 1.4 mg/30 g body weight), hormone ablation by castration, or doxorubicin (6.5 mg/kg every 7 days) and cyclophosphamide (100 mg/kg every 7 days). A non-invasive in vivo method was used to measure pO2 profiles and to calculate oxygen consumption rates (Q(O2)) in tumors. Tumors treated with anti-VEGFR-2 mAb exhibited vessel regression and became hypoxic. Initial vessel regression was followed by a "second wave" of angiogenesis and increases in both pO2 and Q(O2). Hormone ablation led to tumor regression followed by an increase in pO2 coincident with regrowth. Chemotherapy led to tumor growth arrest characterized by constant Q(O2) and elevated pO2. The increased pO2 during anti-VEGFR-2 mAb and hormone ablation therapy may explain the observed beneficial effects of combining antiangiogenic or hormone therapies with radiation treatment. Thus, understanding the microenvironmental dynamics is critical for optimal scheduling of these treatment modalities.
Similar articles
- Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.
Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Kozin SV, et al. Cancer Res. 2001 Jan 1;61(1):39-44. Cancer Res. 2001. PMID: 11196192 - Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases.
Bruns CJ, Liu W, Davis DW, Shaheen RM, McConkey DJ, Wilson MR, Bucana CD, Hicklin DJ, Ellis LM. Bruns CJ, et al. Cancer. 2000 Aug 1;89(3):488-99. Cancer. 2000. PMID: 10931447 - Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions.
Lee CG, Heijn M, di Tomaso E, Griffon-Etienne G, Ancukiewicz M, Koike C, Park KR, Ferrara N, Jain RK, Suit HD, Boucher Y. Lee CG, et al. Cancer Res. 2000 Oct 1;60(19):5565-70. Cancer Res. 2000. PMID: 11034104 - Angiogenesis inhibition in solid tumors.
Rosen LS. Rosen LS. Cancer J. 2001 Nov-Dec;7 Suppl 3:S120-8. Cancer J. 2001. PMID: 11779082 Review. - Anticancer therapy with angiogenesis inhibitors.
Ghilardi C, Bani MR, Giavazzi R. Ghilardi C, et al. Tumori. 2001 Nov-Dec;87(6):S14-6. Tumori. 2001. PMID: 11989610 Review. No abstract available.
Cited by
- Tumor Hypoxia: Impact on Radiation Therapy and Molecular Pathways.
Sørensen BS, Horsman MR. Sørensen BS, et al. Front Oncol. 2020 Apr 21;10:562. doi: 10.3389/fonc.2020.00562. eCollection 2020. Front Oncol. 2020. PMID: 32373534 Free PMC article. Review. - Chemoradiotherapy for gastrointestinal cancers.
Rich TA, Crane C, Lawson JD, Landry J. Rich TA, et al. Curr Oncol Rep. 2005 May;7(3):196-202. doi: 10.1007/s11912-005-0073-2. Curr Oncol Rep. 2005. PMID: 15847710 Review. - Normalization of the vasculature for treatment of cancer and other diseases.
Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Goel S, et al. Physiol Rev. 2011 Jul;91(3):1071-121. doi: 10.1152/physrev.00038.2010. Physiol Rev. 2011. PMID: 21742796 Free PMC article. Review. - Metabolic tumor profiling with pH, oxygen, and glucose chemosensors on a quantum dot scaffold.
Lemon CM, Curtin PN, Somers RC, Greytak AB, Lanning RM, Jain RK, Bawendi MG, Nocera DG. Lemon CM, et al. Inorg Chem. 2014 Feb 17;53(4):1900-15. doi: 10.1021/ic401587r. Epub 2013 Oct 21. Inorg Chem. 2014. PMID: 24143874 Free PMC article. - Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.
Jain RK. Jain RK. J Clin Oncol. 2013 Jun 10;31(17):2205-18. doi: 10.1200/JCO.2012.46.3653. Epub 2013 May 13. J Clin Oncol. 2013. PMID: 23669226 Free PMC article. Review.